THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results